Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

5.00USD
20 Aug 2018
Change (% chg)

$0.05 (+1.01%)
Prev Close
$4.95
Open
$4.95
Day's High
$5.03
Day's Low
$4.95
Volume
1,562
Avg. Vol
48,004
52-wk High
$11.65
52-wk Low
$2.65

Chart for

About

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $32.35
Shares Outstanding(Mil.): 8.91
Dividend: --
Yield (%): --

Financials

  CLBS.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.78 -- --
ROI: -47.46 1.78 14.61
ROE: -70.71 3.28 16.33

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:

10 Apr 2018

BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

* CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

22 Mar 2018

BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan

* CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage:

13 Mar 2018

BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

* CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA

06 Mar 2018

Earnings vs. Estimates